

Dr Andrejs Ivanov

Barts
Cancer Institute
Queen Mary University of London



Research Interests

My main research areas are in Targeted Therapy of Haematological Malignancies, Non-Apoptotic Forms of Cell Death and Activation of Lysosomes for Tumour Clearance.

My research group focuses on:

- Cellular and molecular mechanisms of therapeutic antibody-induced tumour cell death.
- Tumour-host interactions during antibody therapy of leukaemia and lymphoma.
- Determining the biological basis for the most effective chemotherapy and antibody combinations for successful leukaemia and lymphoma therapy.
- Mechanisms of tumour cell resistance to antibody therapy.

Major Funders

- Higher Education Funding Council for England

Contact Details

Email: andrejs.ivanov@qmul.ac.uk



Barts and The London
School of Medicine and Dentistry

www.bci.qmul.ac.uk

Dr Andrejs Ivanov

Barts
Cancer Institute
Queen Mary University of London



Recent Publications

- **Ivanov A**, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, Shah PP, Hewitt G, Korolchuk VI, Passos JF, Wu H, Berger SL, Adams PD. Lysosome-mediated processing of chromatin in senescence. *J Cell Biol.* 2013 Jul 8;202(1):129-43.
- Alduaij W, **Ivanov A**, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. *Blood.* 2011 Apr 28;117(17):4519-29.
- **Ivanov A**, and Adams P.D., A damage limitation exercise. *Nat Cell Biol.* 2011 Mar;13(3):193-5.
- **Ivanov A**, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. *J Clin Invest.* 2009 Aug;119(8):2143-59.
- **Ivanov A**, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. *Clin Cancer Res.* 2008 Aug 1;14(15):4925-34.